Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

ACHOLEPLASMA LAIDLAWII BRP (1ML)

ACHOLEPLASMA LAIDLAWII BRP (1ML)

ND

DISCOVER
Bisacodyl for system suitability CRS, 5mg

Bisacodyl for system suitability CRS, 5mg

603-50-9

DISCOVER
NALOXONE FOR PEAK IDENTIFICATION CRS (5.1 MG)

NALOXONE FOR PEAK IDENTIFICATION CRS (5.1 MG)

51481-60-8

DISCOVER
TESTOSTERONE DECANOATE FOR SYSTEM SUITABILITY CRS (0.4 MG)

TESTOSTERONE DECANOATE FOR SYSTEM SUITABILITY CRS (0.4 MG)

5721-91-5

DISCOVER
PACLITAXEL CRS (40 MG)

PACLITAXEL CRS (40 MG)

33069-62-4

DISCOVER
PACLITAXEL IMPURITY C CRS (10MG)

PACLITAXEL IMPURITY C CRS (10MG)

153415-45-3

DISCOVER
PACLITAXEL NATURAL FOR PEAK IDENTIFICATION CRS (10 MG)

PACLITAXEL NATURAL FOR PEAK IDENTIFICATION CRS (10 MG)

33069-62-4

DISCOVER
METOLAZONE CRS (80 MG)

METOLAZONE CRS (80 MG)

17560-51-9

DISCOVER
METOLAZONE FOR SYSTEM SUITABILITY CRS (10 MG)

METOLAZONE FOR SYSTEM SUITABILITY CRS (10 MG)

17560-51-9

DISCOVER
MOXIFLOXACIN HYDROCHLORIDE CRS (120 MG)

MOXIFLOXACIN HYDROCHLORIDE CRS (120 MG)

186826-86-8

DISCOVER
THIORIDAZINE CRS (10 MG)

THIORIDAZINE CRS (10 MG)

50-52-2

DISCOVER
MIRTAZAPINE CRS (10 MG)

MIRTAZAPINE CRS (10 MG)

61337-67-5

DISCOVER